Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression

 
• By Anju Ghangurde

R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.

Will IRA provisions derail small molecules R&D? • Source: Shutterstock

More from R&D

More from Scrip